A Phase 2 interventional study of KAE609 in Malaria, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Vietnam. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2016-10-31.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Malaria by Novartis — 3 open to participants now, 3 under way, none of them phase 3. Malaria · Novartis.
Among the 24 studies in Malaria by Novartis, this one is the 16th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2014, is one of 6 in phase 2, and was the 11th registered.
1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.
Browse Malaria studies →3 of the 24 studies in Malaria by Novartis are open now, in 6 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Burkina Faso, Côte D'Ivoire, Gabon and 3 more countries
Ages 2–100
Novartis Pharmaceuticals
Ages 0 days–12 mo
Novartis Pharmaceuticals
Ages 10–99 · Healthy volunteers
By country, each count listing its studies:
Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.
This study: 20 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 5 · Phase 4 5
First in 2001; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 252 across 938 interventional studies indexed under Malaria.
Median enrollment 57 across the 21 interventional studies, 254 across the 2 observational. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Malaria by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07896746Novartis PharmaceuticalsFactors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and Rwanda | 2027-01-30 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Malaria by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to determine the Minimum Inhibitory Concentration of KAE609 in adult male patients with acute, uncomplicated malaria due to P.falciparum monoinfection after single dosing with KAE609
There will be a total of approximately 45 patients recruited into this study and six doses of KAE609 and will be investigated.The dose groups will run in sequence. Patient will be given a single dose of KAE609 and be followed up for 42 days.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of KAE609 30 mg
Drug: KAE609
Single dose of KAE609 20 mg
Drug: KAE609
Single dose of KAE609 10 mg
Drug: KAE609
Single dose of KAE609 15 mg
Drug: KAE609
Patients will receive KAE609 single dose at a different dose level in each cohort.
Minimum Inhibitory Concentration (MIC) of KAE609
To observe the exposure-response (PK/PD) relationship for a single dose of KAE609. The key parameter is MIC, defined as the concentration at which the relative rate of change in parasitemia is equal to zero. Approximation of MIC will assist in identifying the optimal dose of KAE609, which will be one component of a future combination antimalarial. MIC could not be determined due to small sample size no data was collected from any participants.
Time frame: Up to Day 8 after a single dose of KAE609
Median Time to Parasite Clearance
Parasite clearance time will be estimated using thick/thin blood films.
Time frame: pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 54, 60, 66, 72 hours post dose of KAE609
Median Time to Fever Clearance
Fever is monitored on participants every 4 hours for the first 24 hours, then every 6 hours until negative reading obtained.
Time frame: Day 1 to Day 5
Percentage of Patients PCR-corrected Cure Rate by Day 28, Day 35 & Day 42
PCR-corrected cure rate after a single dose of KAE609 by Day 28, Day 35 \& Day 42. PCR-corrected cure rate accounts for failures due to reappearance of parasites that were present in the blood before treatment (i.e. recrudescent infection) but not for failures due to a post-treatment inoculation (i.e. new infection).
Time frame: Day 28, Day 35 & Day 42
| Milestone | Dose 1: 30 mg | Dose 2: 20 mg | Dose 3: 10 mg | Dose 4: 15 mg |
|---|---|---|---|---|
| Started | 7 | 4 | 7 | 7 |
| Completed | 4 | 2 | 2 | 1 |
| Not completed | 3 | 2 | 5 | 6 |
| Withdrew: Unsatisfactory therapeutic effect | 3 | 2 | 5 | 6 |
To observe the exposure-response (PK/PD) relationship for a single dose of KAE609. The key parameter is MIC, defined as the concentration at which the relative rate of change in parasitemia is equal to zero. Approximation of MIC will assist in identifying the optimal dose of KAE609, which will be one component of a future combination antimalarial. MIC could not be determined due to small sample size no data was collected from any participants.
No measurements were reported for this outcome.
Parasite clearance time will be estimated using thick/thin blood films.
| hours | Dose 1: 30 mg | Dose 2: 20 mg | Dose 3: 10 mg | Dose 4: 15 mg |
|---|---|---|---|---|
| Median Time to Parasite Clearance | 24.00 (12.00 to 48.00) | 63.00 (36.02 to 72.00) | 54.00 (36.05 to NA) | 60.00 (36.00 to 72.00) |
Fever is monitored on participants every 4 hours for the first 24 hours, then every 6 hours until negative reading obtained.
| hours | Dose 1: 30 mg | Dose 2: 20 mg | Dose 3: 10 mg | Dose 4: 15 mg |
|---|---|---|---|---|
| Median Time to Fever Clearance | 9.83 (0.83 to 11.92) | 12.38 (3.83 to 29.83) | 15.75 (0.75 to 15.83) | 11.83 (4.83 to 35.83) |
PCR-corrected cure rate after a single dose of KAE609 by Day 28, Day 35 \& Day 42. PCR-corrected cure rate accounts for failures due to reappearance of parasites that were present in the blood before treatment (i.e. recrudescent infection) but not for failures due to a post-treatment inoculation (i.e. new infection).
| Percentage of Patients | Dose 1: 30 mg | Dose 2: 20 mg | Dose 3: 10 mg | Dose 4: 15 mg |
|---|---|---|---|---|
| Day 28 | 57.1 | 50.0 | 28.6 | 14.3 |
| Day 35 | 57.1 | 50.0 | 28.6 | 14.3 |
| Day 42 | 57.1 | 50.0 | 28.6 | 14.3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose 1: 30mg | — | 0/7 (0%) | 4/7 (57.1%) |
| Dose 2: 20mg | — | 0/4 (0%) | 3/4 (75%) |
| Dose 3: 10mg | — | 0/7 (0%) | 7/7 (100%) |
| Dose 4: 15mg | — | 0/7 (0%) | 5/7 (71.4%) |
| Event | Dose 1: 30mg | Dose 2: 20mg | Dose 3: 10mg | Dose 4: 15mg |
|---|---|---|---|---|
| Blood alkaline phosphatase increasedInvestigations | 1/7 | 2/4 | 3/7 | 4/7 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/7 | 1/4 | 3/7 | 1/7 |
| Abnormal faecesGastrointestinal disorders | 0/7 | 1/4 | 0/7 | 0/7 |
| HeadacheNervous system disorders | 1/7 | 1/4 | 0/7 | 0/7 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/7 | 1/4 | 0/7 | 0/7 |
| AnaemiaBlood and lymphatic system disorders | 0/7 | 0/4 | 1/7 | 0/7 |
| Abdominal pain upperGastrointestinal disorders | 0/7 | 0/4 | 1/7 | 0/7 |
| DiarrhoeaGastrointestinal disorders | 0/7 | 0/4 | 0/7 | 1/7 |
| NauseaGastrointestinal disorders | 1/7 | 0/4 | 1/7 | 0/7 |
| Alanine aminotransferase increasedInvestigations | 1/7 | 0/4 | 0/7 | 0/7 |
| Age, Continuous(years) | Dose 1: 30 mg | Dose 2: 20 mg | Dose 3: 10 mg | Dose 4: 15 mg | Total |
|---|---|---|---|---|---|
| Mean | 32.7 ± 11.84 | 32.8 ± 7.93 | 30.6 ± 8.24 | 34.7 ± 8.79 | 32.7 ± 9.04 |
| Sex/Gender, Customized(participants) | Dose 1: 30 mg | Dose 2: 20 mg | Dose 3: 10 mg | Dose 4: 15 mg | Total |
|---|---|---|---|---|---|
| MALE | 7 | 4 | 7 | 7 | 25 |
The record gives a start of Jan 2014, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NITD 609